|
US6653341B1
(en)
*
|
1998-06-17 |
2003-11-25 |
Eisai Co., Ltd. |
Methods and compositions for use in treating cancer
|
|
US8097648B2
(en)
*
|
1998-06-17 |
2012-01-17 |
Eisai R&D Management Co., Ltd. |
Methods and compositions for use in treating cancer
|
|
AU762998B2
(en)
|
1998-06-17 |
2003-07-10 |
Eisai R&D Management Co., Ltd. |
Macrocyclic analogs and methods of their use and preparation
|
|
DE10037310A1
(de)
*
|
2000-07-28 |
2002-02-07 |
Asta Medica Ag |
Neue Indolderivate und deren Verwendung als Arzneimittel
|
|
EP1531846A4
(en)
*
|
2002-02-27 |
2006-04-19 |
Us Gov Health & Human Serv |
CONJUGATES OF LIGAND, LINK AND CYTOTOXIC AGENS, AND RELATED COMPOSITIONS AND USE PROCESSES
|
|
KR101208266B1
(ko)
|
2002-03-22 |
2012-12-05 |
에자이 알앤드디 매니지먼트 가부시키가이샤 |
헤미아스텔린 유도체 및 이의 용도
|
|
US20050075395A1
(en)
*
|
2003-05-28 |
2005-04-07 |
Gary Gordon |
Continuous dosing regimen
|
|
CA2526385C
(en)
*
|
2003-05-29 |
2008-07-22 |
Abbott Laboratories |
Continuous dosing regimen with abt-751
|
|
EP1653953A4
(en)
*
|
2003-07-29 |
2010-05-05 |
Eisai R&D Man Co Ltd |
METHOD AND DEVICES FOR THE MEDICINAL PRODUCTION
|
|
USRE45324E1
(en)
*
|
2004-06-03 |
2015-01-06 |
Eisai R&D Management Co., Ltd. |
Intermediates for the preparation of analogs of halichondrin B
|
|
CN1993342A
(zh)
*
|
2004-06-03 |
2007-07-04 |
卫材株式会社 |
用于制备软海绵素b的中间体
|
|
US20060045846A1
(en)
*
|
2004-08-30 |
2006-03-02 |
Horstmann Thomas E |
Reagents and methods for labeling terminal olefins
|
|
US20060154312A1
(en)
*
|
2004-12-09 |
2006-07-13 |
Sergei Agoulnik |
Tubulin isotype screening in cancer therapy using halichondrin B analogs
|
|
BRPI0817909B1
(pt)
|
2007-10-03 |
2022-06-21 |
Eisai R&D Management Co., Ltd |
Métodos de obtenção e de preparação de uma composição diastereomericamente pura, compostos, e método para produzir os referidos compostos
|
|
RU2517167C2
(ru)
*
|
2008-04-04 |
2014-05-27 |
Эйсай Ар Энд Ди Менеджмент Ко., Лтд. |
Аналоги галихондрина в
|
|
RU2476216C1
(ru)
*
|
2009-03-30 |
2013-02-27 |
Эйсай Ар Энд Ди Менеджмент Ко., Лтд. |
Липосомальная композиция
|
|
US20120058178A1
(en)
|
2009-03-30 |
2012-03-08 |
Eisai R&D Management Co., Ltd. |
Liposome Composition
|
|
EP2415464B1
(en)
|
2009-03-30 |
2017-05-10 |
Eisai R&D Management Co., Ltd. |
Method for producing liposome composition
|
|
EP2420504B1
(en)
*
|
2009-04-14 |
2014-01-15 |
Nissan Chemical Industries, Ltd. |
Method for producing tetrahydropyran compound and intermediate thereof
|
|
MX2012008510A
(es)
*
|
2010-01-26 |
2012-11-21 |
Eisai R&D Man Co Ltd |
Derivados de furo [3, 2-b] pirano utiles en la sintesis de analogos de halicondrina b.
|
|
US9637795B2
(en)
|
2011-03-18 |
2017-05-02 |
Eisai R&D Management Co., Ltd. |
Methods and compositions for predicting response to eribulin
|
|
WO2012147900A1
(en)
|
2011-04-28 |
2012-11-01 |
Eisai R&D Management Co., Ltd. |
Microreactor process for halichondrin b analog synthesis
|
|
US9945862B2
(en)
|
2011-06-03 |
2018-04-17 |
Eisai R&D Management Co., Ltd. |
Biomarkers for predicting and assessing responsiveness of thyroid and kidney cancer subjects to lenvatinib compounds
|
|
CA2857385A1
(en)
|
2011-11-30 |
2013-06-06 |
Alphora Research Inc. |
Process for preparation of (3r)-2,4-di-leaving group-3-methylbut-1-ene
|
|
EP2791123B1
(en)
|
2011-12-16 |
2018-07-18 |
Sandoz AG |
Process for preparation of 3-((2s,5s)-4-methylene-5-(3-oxopropyl)tetrahydrofuran-2-yl) propanol derivatives and intermediates useful thereof
|
|
IN2014MN01521A
(xx)
*
|
2011-12-29 |
2015-05-01 |
Alphora Res Inc |
|
|
US9278979B2
(en)
|
2012-03-30 |
2016-03-08 |
Alphora Research Inc. |
Synthetic process for preparation of macrocyclic C1-keto analogs of halichondrin B and intermediates useful therein
|
|
EP2928464A1
(en)
|
2012-12-04 |
2015-10-14 |
Eisai R&D Management Co., Ltd. |
Use of eribulin in the treatment of breast cancer
|
|
AR096238A1
(es)
|
2013-05-15 |
2015-12-16 |
Alphora Res Inc |
Proceso para preparar derivados de 3-((2s,5s)-4-metilen-5-(3-oxopropil)tetrahidrofuran-2-il)propanol e intermediarios útiles para el mismo
|
|
US9549922B2
(en)
|
2013-06-26 |
2017-01-24 |
Eisai R&D Management Co., Ltd. |
Use of eribulin and lenvatinib as combination therapy for treatment of cancer
|
|
WO2015000070A1
(en)
|
2013-07-03 |
2015-01-08 |
Alphora Research Inc. |
Synthetic process for preparation of macrocyclic c1-keto analogs of halichondrin b and intermediates useful therein including intermediates containing -so2-(p-tolyl) groups
|
|
CN103483352A
(zh)
*
|
2013-10-18 |
2014-01-01 |
李友香 |
抗肿瘤的药用原料药
|
|
EP3066102B1
(en)
|
2013-11-04 |
2020-02-26 |
Eisai R&D Management Co., Ltd. |
Macrocyclization reactions and intermediates useful in the synthesis of analogs of halichondrin b
|
|
CA2931788C
(en)
|
2013-12-06 |
2022-05-24 |
Eisai R&D Management Co., Ltd. |
Methods useful in the synthesis of halichondrin b analogs
|
|
CN104860978A
(zh)
*
|
2014-02-20 |
2015-08-26 |
正大天晴药业集团股份有限公司 |
软海绵素b类似物的合成中间体
|
|
TW201617326A
(zh)
|
2014-03-06 |
2016-05-16 |
Ａｌｐｈｏｒａ研發股份有限公司 |
（ｓ）－１－（（２ｒ，３ｒ，４ｓ，５ｓ）－５－烯丙－３－甲氧－４－（對甲苯磺醯甲基）四氫呋喃－２－基）－３－氨基丙－２－醇之結晶衍生物
|
|
KR20170039096A
(ko)
*
|
2014-05-28 |
2017-04-10 |
에자이 알앤드디 매니지먼트 가부시키가이샤 |
암의 치료에 있어서 에리불린의 용도
|
|
EP3160970A4
(en)
|
2014-06-30 |
2017-12-27 |
President and Fellows of Harvard College |
Synthesis of halichondrin analogs and uses thereof
|
|
CA2957005C
(en)
|
2014-08-28 |
2021-10-12 |
Eisai R&D Management Co., Ltd. |
High-purity quinoline derivative and method for manufacturing same
|
|
WO2016038624A1
(en)
|
2014-09-09 |
2016-03-17 |
Cipla Limited |
"process for the preparation of macrocyclic ketone analogs of halichondrin b or pharmaceutically acceptable salts and intermediates thereof"
|
|
CN105713031B
(zh)
*
|
2014-12-05 |
2021-05-07 |
正大天晴药业集团股份有限公司 |
一种用于制备艾日布林的中间体及其制备方法
|
|
PL3263106T3
(pl)
|
2015-02-25 |
2024-04-02 |
Eisai R&D Management Co., Ltd. |
Sposób tłumienia goryczy pochodnej chinoliny
|
|
JP6951248B2
(ja)
|
2015-03-04 |
2021-10-20 |
メルク・シャープ・アンド・ドーム・コーポレーションＭｅｒｃｋ Ｓｈａｒｐ ＆ Ｄｏｈｍｅ Ｃｏｒｐ． |
がんを治療するための、ｐｄ−１アンタゴニスト及びエリブリンの組合せ
|
|
KR20170122809A
(ko)
|
2015-03-04 |
2017-11-06 |
머크 샤프 앤드 돔 코포레이션 |
암을 치료하기 위한 pd-1 길항제 및 vegfr/fgfr/ret 티로신 키나제 억제제의 조합
|
|
WO2016176560A1
(en)
|
2015-04-30 |
2016-11-03 |
President And Fellows Of Harvard College |
Chromium-mediated coupling and application to the synthesis of halichondrins
|
|
MX2021002629A
(es)
|
2015-05-07 |
2022-05-13 |
Eisai R&D Man Co Ltd |
Reacciones de macrociclizacion e intermediarios y otros fragmentos utiles en la sintesis de macrolidos de halicondrina.
|
|
WO2016182850A1
(en)
|
2015-05-08 |
2016-11-17 |
Albany Molecular Research, Inc. |
Methods and intermediates for the preparation of omacetaxine and cephalotaxine derivatives thereof
|
|
WO2016204193A1
(ja)
|
2015-06-16 |
2016-12-22 |
株式会社ＰＲＩＳＭ Ｐｈａｒｍａ |
抗がん剤
|
|
RU2732575C2
(ru)
*
|
2016-02-12 |
2020-09-21 |
Эйсай Ар Энд Ди Менеджмент Ко., Лтд. |
Промежуточные продукты в синтезе эрибулина и соответствующие способы синтеза
|
|
JP7015237B2
(ja)
|
2016-04-28 |
2022-02-02 |
エーザイ・アール・アンド・ディー・マネジメント株式会社 |
腫瘍の成長を抑制する方法
|
|
KR20190009326A
(ko)
*
|
2016-05-26 |
2019-01-28 |
닥터 레디스 레보러터리즈 리미티드 |
에리불린 및 그의 중간체의 제조방법
|
|
KR102404629B1
(ko)
|
2016-06-30 |
2022-06-02 |
에자이 알앤드디 매니지먼트 가부시키가이샤 |
할리콘드린 마크롤리드 및 그의 유사체의 합성에 유용한 프린스 반응 및 중간체
|
|
KR20190082782A
(ko)
|
2016-10-14 |
2019-07-10 |
머크 샤프 앤드 돔 코포레이션 |
요로상피암을 치료하기 위한 pd-1 길항제 및 에리불린의 조합
|
|
JP6978758B2
(ja)
|
2016-11-11 |
2021-12-08 |
プレジデント アンド フェローズ オブ ハーバード カレッジ |
パラジウム媒介ケトール化
|
|
WO2018096478A2
(en)
|
2016-11-23 |
2018-05-31 |
Dr. Reddy’S Laboratories Limited |
Process for preparation of eribulin and intermediates thereof
|
|
KR101880939B1
(ko)
|
2017-01-02 |
2018-08-17 |
연성정밀화학(주) |
에리불린 메실산염의 제조 중간체 및 그의 제조방법
|
|
KR101991710B1
(ko)
|
2017-12-14 |
2019-06-21 |
연성정밀화학(주) |
에리불린 메실산염의 제조 중간체 및 그의 제조방법
|
|
ES2932832T3
(es)
*
|
2017-01-02 |
2023-01-26 |
Yonsung Fine Chemical Co Ltd |
Intermedio de producción de mesilato de eribulina, y método para producir el mismo
|
|
CN108341828B
(zh)
*
|
2017-01-24 |
2021-04-06 |
江苏恒瑞医药股份有限公司 |
用于制备艾日布林的方法及其中间体
|
|
CN108341738B
(zh)
*
|
2017-01-24 |
2022-10-21 |
江苏恒瑞医药股份有限公司 |
用于制备艾日布林的方法及其中间体
|
|
US9938288B1
(en)
|
2017-04-05 |
2018-04-10 |
President And Fellows Of Harvard College |
Macrocyclic compound and uses thereof
|
|
HRP20221385T1
(hr)
|
2017-04-05 |
2023-01-06 |
President And Fellows Of Harvard College |
Makrociklički spoj i njegova uporaba
|
|
US11498892B2
(en)
|
2017-07-06 |
2022-11-15 |
President And Fellows Of Harvard College |
Fe/Cu-mediated ketone synthesis
|
|
IL271660B
(en)
|
2017-07-06 |
2022-09-01 |
Harvard College |
Synthesis of the Lichondrins
|
|
US20190046513A1
(en)
|
2017-08-10 |
2019-02-14 |
Huya Bioscience International, Llc |
Combination therapies of hdac inhibitors and tubulin inhibitors
|
|
CN109694379B
(zh)
*
|
2017-10-24 |
2020-09-11 |
江苏恒瑞医药股份有限公司 |
用于制备艾日布林的中间体及其制备方法
|
|
WO2019093776A1
(ko)
|
2017-11-09 |
2019-05-16 |
연성정밀화학(주) |
에리불린 메실산염의 제조 중간체 및 그의 제조방법
|
|
CN111566113B
(zh)
|
2017-11-15 |
2024-01-09 |
哈佛大学的校长及成员们 |
大环化合物及其用途
|
|
WO2019097073A1
(en)
|
2017-11-20 |
2019-05-23 |
Basilea Pharmaceutica International AG |
Pharmaceutical combinations for use in the treatment of neoplastic diseases
|
|
US11008296B2
(en)
|
2017-11-21 |
2021-05-18 |
Natco Pharma Limited |
Intermediates for the preparation of eribulin thereof
|
|
MX2020006945A
(es)
|
2018-01-03 |
2020-11-09 |
Eisai R&D Man Co Ltd |
Reaccion de prins y compuestos utiles en la sintesis de macrolidos de halicondrina y analogos de los mismos.
|
|
WO2019211877A1
(en)
|
2018-05-03 |
2019-11-07 |
Cipla Limited |
Process for the preparation of macrocyclic ketone analogs of halichondrin b
|
|
WO2020008382A1
(en)
*
|
2018-07-04 |
2020-01-09 |
Dr. Reddy’S Laboratories Limited |
Process for preparation of eribulin and intermediates thereof
|
|
CN112437775A
(zh)
*
|
2018-07-20 |
2021-03-02 |
雷迪博士实验室有限公司 |
用于制备艾日布林及其中间体的纯化方法
|
|
CN113166096A
(zh)
*
|
2018-10-09 |
2021-07-23 |
雷迪博士实验室有限公司 |
制备艾立布林的方法及其中间体
|
|
US11447499B2
(en)
|
2019-06-14 |
2022-09-20 |
Rk Pharma Inc. |
Process for the preparation of eribulin mesylate intermediate
|
|
JP2022537785A
(ja)
|
2019-06-21 |
2022-08-29 |
カウンスィル オブ サイエンティフィック アンド インダストリアル リサーチ |
ホモプロパルギルアルコールを調製するための化学酵素的プロセス
|
|
US11083705B2
(en)
|
2019-07-26 |
2021-08-10 |
Eisai R&D Management Co., Ltd. |
Pharmaceutical composition for treating tumor
|
|
CA3159541A1
(en)
|
2019-11-07 |
2021-05-14 |
Eisai R&D Management Co., Ltd. |
Anti-mesothelin eribulin antibody-drug conjugates and methods of use
|
|
CN113135876A
(zh)
*
|
2020-01-16 |
2021-07-20 |
南通诺泰生物医药技术有限公司 |
艾日布林及其中间体的制备方法
|
|
CN114845739A
(zh)
*
|
2020-01-22 |
2022-08-02 |
上海森辉医药有限公司 |
艾日布林衍生物的药物偶联物、其制备方法及其在医药上的应用
|
|
KR102377262B1
(ko)
|
2020-05-11 |
2022-03-22 |
연성정밀화학(주) |
결정성 에리불린 염
|
|
IL279168B
(en)
*
|
2020-12-02 |
2022-04-01 |
Finetech Pharmaceutical Ltd |
A process for the preparation of eribulin
|
|
CN113354659B
(zh)
|
2021-06-08 |
2022-04-08 |
江苏慧聚药业股份有限公司 |
甲磺酸艾日布林的合成
|
|
WO2023001300A1
(zh)
*
|
2021-07-22 |
2023-01-26 |
上海森辉医药有限公司 |
艾日布林衍生物的药物偶联物
|
|
WO2023212746A2
(en)
*
|
2022-04-30 |
2023-11-02 |
William Marsh Rice University |
A unified strategy for the total syntheses of eribulin and a macrolactam analogue of halichondrin b
|